Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs OurView Health

Eve
Graded #212

Lower grade

vs+1.5999999999999943
OurView Health
Graded #167

Higher grade

The verdict

OurView Health takes it — 67.6/100 to 66/100, but only just.

OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications. Eve is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOurView Health +22
54
76
Dose & formulationEve +24
88
64
Clinical oversightEven
79
79
Labs & monitoringOurView Health +1
52
53
FulfillmentOurView Health +3
67
70
Contract termsOurView Health +4
41
45
Eve · left barOurView Health · right bar

The numbers

MetricEveOurView Health
WeighScore66/10067.6/100
GradeCC
Scorecard rank#212#167
Semaglutide$195/mo (compounded)$75/mo (starting dose, compounded)
Tirzepatide$195/mo (compounded)$135/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Eve

Graded #212 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
OurView Health

Graded #167 · C

Strengths

  • Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
  • Clear product pricing with no contracts; medication shipped to your door (30-day supply)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
  • Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)

Where it loses points

  • 'Starting at' prices likely require Savings Club membership and/or a longer plan
  • Compounding pharmacy partner not named ('licensed third-party pharmacy')
  • 'LegitScript Approved' is stated on the site but was not independently verified here
  • Operating medical entity not clearly named (site operated by a marketing agency)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard